<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: J&amp;J&#8217;s Fort Washington Plant Cited for Quality Problems; Two Vice-Chairmen Appointed</title>
	<atom:link href="http://blog.pharmtech.com/2010/12/16/j-two-vice-chairmen-appointed/feed/" rel="self" type="application/rss+xml" />
	<link>http://blog.pharmtech.com/2010/12/16/j-two-vice-chairmen-appointed/</link>
	<description>The blog of Pharmaceutical Technology magazine</description>
	<lastBuildDate>Thu, 09 May 2013 23:30:55 -0400</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: Reuven</title>
		<link>http://blog.pharmtech.com/2010/12/16/j-two-vice-chairmen-appointed/comment-page-1/#comment-34145</link>
		<dc:creator>Reuven</dc:creator>
		<pubDate>Sat, 25 Dec 2010 16:19:05 +0000</pubDate>
		<guid isPermaLink="false">http://blog.pharmtech.com/?p=3725#comment-34145</guid>
		<description>J&amp;J&#039;s EIR is the first time I see the the FDA sees OOT the same way as OOT,including the investigation efforts and the APR review.</description>
		<content:encoded><![CDATA[<p>J&amp;J&#8217;s EIR is the first time I see the the FDA sees OOT the same way as OOT,including the investigation efforts and the APR review.</p>
]]></content:encoded>
	</item>
</channel>
</rss>
